ATE274344T1 - Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium - Google Patents

Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium

Info

Publication number
ATE274344T1
ATE274344T1 AT99935347T AT99935347T ATE274344T1 AT E274344 T1 ATE274344 T1 AT E274344T1 AT 99935347 T AT99935347 T AT 99935347T AT 99935347 T AT99935347 T AT 99935347T AT E274344 T1 ATE274344 T1 AT E274344T1
Authority
AT
Austria
Prior art keywords
coating
active ingredient
sustained release
phenytoin sodium
pharmaceutical preparation
Prior art date
Application number
AT99935347T
Other languages
German (de)
English (en)
Inventor
Elliott Beiman
Fred Landsman
Original Assignee
Cascade Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/111,188 external-priority patent/US5968554A/en
Application filed by Cascade Dev Inc filed Critical Cascade Dev Inc
Application granted granted Critical
Publication of ATE274344T1 publication Critical patent/ATE274344T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99935347T 1998-07-07 1999-06-25 Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium ATE274344T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/111,188 US5968554A (en) 1998-07-07 1998-07-07 Sustained release pharmaceutical preparation
US09/338,716 US6312728B1 (en) 1998-07-07 1999-06-23 Sustained release pharmaceutical preparation
PCT/US1999/014204 WO2000001369A1 (en) 1998-07-07 1999-06-25 Sustained release pharmaceutical preparation

Publications (1)

Publication Number Publication Date
ATE274344T1 true ATE274344T1 (de) 2004-09-15

Family

ID=26808709

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99935347T ATE274344T1 (de) 1998-07-07 1999-06-25 Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium

Country Status (10)

Country Link
US (1) US6312728B1 (https=)
EP (1) EP1094790B9 (https=)
JP (1) JP2003524592A (https=)
AT (1) ATE274344T1 (https=)
AU (1) AU5084299A (https=)
CA (1) CA2337046C (https=)
DE (1) DE69919713T2 (https=)
ES (1) ES2226412T3 (https=)
IL (1) IL140761A0 (https=)
WO (1) WO2000001369A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20040043067A1 (en) * 2002-06-19 2004-03-04 Salamone Joseph C. Fluorosiloxane matrix controlled diffusion drug delivery systems
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
WO2005030179A1 (en) * 2003-09-29 2005-04-07 Cj Corporation Sustained-release formulations
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
WO2005117697A2 (en) * 2004-05-28 2005-12-15 Narayanan Ramasubramanian Unified indigestion package and process for patient compliance with prescribed medication regimen
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
AU2007214487A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
CA2687130C (en) * 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CA3165418A1 (en) 2019-12-27 2021-07-01 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
US20230190831A1 (en) 2020-04-17 2023-06-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
TW202228653A (zh) 2020-09-18 2022-08-01 美商艾弗洛生物科技股份有限公司 細菌之固體劑型
EP4236973A1 (en) 2020-10-29 2023-09-06 Evelo Biosciences, Inc. Compositions comprising spirulina components
JP2024501481A (ja) 2020-12-14 2024-01-12 エヴェロ バイオサイエンシズ,インコーポレーテッド 細胞外小胞調製物
US20240226188A9 (en) 2020-12-22 2024-07-11 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
US20240423924A1 (en) 2021-01-26 2024-12-26 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
WO2022182707A1 (en) 2021-02-26 2022-09-01 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
TW202304415A (zh) 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
US20250114411A1 (en) 2021-09-24 2025-04-10 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023114296A2 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle preparations
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5540945A (en) * 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
US5368861A (en) * 1989-10-26 1994-11-29 Nippon Shinyaku Co., Ltd. Gastric preparation with sustained release
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5188836A (en) 1990-07-27 1993-02-23 Warner-Lambert Company Sustained release formulations
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US5968554A (en) * 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
EP1094790B9 (en) 2005-05-04
CA2337046A1 (en) 2000-01-13
EP1094790B1 (en) 2004-08-25
US6312728B1 (en) 2001-11-06
DE69919713D1 (de) 2004-09-30
CA2337046C (en) 2005-08-16
AU5084299A (en) 2000-01-24
EP1094790A1 (en) 2001-05-02
ES2226412T3 (es) 2005-03-16
IL140761A0 (en) 2002-02-10
DE69919713T2 (de) 2005-09-22
EP1094790A4 (en) 2003-03-12
JP2003524592A (ja) 2003-08-19
WO2000001369A1 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
ATE274344T1 (de) Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
ATE99927T1 (de) Pharmazeutische formulierungen.
AU4989997A (en) Soluble form osmotic dose delivery system
DK1406568T3 (da) Sekventielle lægemiddelafgivelsessystemer
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
DE69620606D1 (de) Feste oral anzuwendende arzeneiform
DE68909772D1 (de) Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
ATE541562T1 (de) Ibuprofen-suspension
ATE292453T1 (de) Antivirale arznei
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
DE60018629D1 (de) Carbamazepinformulierung mit verzögerter Freigabe
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
GEP20043377B (en) Pharmaceutical Complex
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
ATE258046T1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
FR2803521B1 (fr) Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
YU25297A (en) A controlled release formulation for poorly soluble basic drugs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties